Anthonie van der Wekken

University of Groningen

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Sanjay Popat

Professor of Thoracic Oncology

Institute of Cancer Research

UNITED KINGDOM

View details

Pilar Garrido López

Head Medical Oncology Department

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

SPAIN

View details

Luka Brcic

Medical University of Graz

AUSTRIA

View details

Matthew Groves

Assistant Professor

Rijksuniversiteit Groningen

NETHERLANDS

View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anthonie van der Wekken

Research Interests

Explore related searches

Contact this professor

Articles (10)

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

Collaborators (5)

Sanjay Popat

Pilar Garrido López

Luka Brcic

Matthew Groves

Benjamin Solomon

Make your next move.